PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för tasisulam. Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

14 hits

Bibliografisk träff 2019-11-04

Structural complementarity facilitates E7820-mediated degradation of RBM39 by DCAF15.

Faust TB, Yoon H, Nowak RP, Donovan KA, Li Z, Cai Q, Eleuteri NA, Zhang T, Gray NS, Fischer ES.

Nat Chem Biol · research support, non-u.s. gov't; research-article; research support, u.s. gov't, non-p.h.s.; journal article; research support, n.i.h., extramural · DOI 10.1038/s41589-019-0378-3

Bibliografisk träff 2019-03-01

Efficient synthesis of carbon-11 labelled acylsulfonamides using [<sup>11</sup>C]CO carbonylation chemistry.

van der Wildt B, Shen B, Chin FT.

Chem Commun (Camb) · research-article; journal article · DOI 10.1039/c8cc09661a

Bibliografisk träff 2018-06-01

Physiologically Based Pharmacokinetic Modelling of Cytochrome P450 2C9-Related Tolbutamide Drug Interactions with Sulfaphenazole and Tasisulam.

Perkins EJ, Posada M, Kellie Turner P, Chappell J, Ng WT, Twelves C.

Eur J Drug Metab Pharmacokinet · research-article; journal article · DOI 10.1007/s13318-017-0447-5

Bibliografisk träff 2016-12-24

Synthesis of a Sulfonimidamide-Based Analog of Tasisulam and Its Biological Evaluation in the Melanoma Cell Lines SKMel23 and A375.

Steinkamp AD, Schmitt L, Chen X, Fietkau K, Heise R, Baron JM, Bolm C.

Skin Pharmacol Physiol · journal article · DOI 10.1159/000453042

Bibliografisk träff 2014-09-28

An innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumors.

Jotte RM, Von Hoff DD, Braiteh F, Becerra CR, Richards DA, Smith DA, Garbo L, Stephenson J, Conkling PR, Robert-Vizcarrondo F, Chen J, Turner PK, Chow KH, Tai DF, Ilaria R.

Invest New Drugs · research support, non-u.s. gov't; multicenter study; clinical trial, phase i; journal article · DOI 10.1007/s10637-014-0160-z

Bibliografisk träff 2014-03-26

A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanoma.

Hamid O, Ilaria R, Garbe C, Wolter P, Maio M, Hutson TE, Arance A, Lorigan P, Lee J, Hauschild A, Mohr P, Hahka-Kemppinen M, Kaiser C, Turner PK, Conti I, Grob JJ.

Cancer · clinical trial, phase iii; comparative study; research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1002/cncr.28635

Bibliografisk träff 2013-02-01

A phase I study of tasisulam sodium using an albumin-tailored dose in Japanese patients with advanced solid tumors.

Fujiwara Y, Ando Y, Mukohara T, Kiyota N, Chayahara N, Mitsuma A, Inada-Inoue M, Sawaki M, Ilaria R, Kellie Turner P, Funai J, Maeda K, Minami H.

Cancer Chemother Pharmacol · research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1007/s00280-013-2092-2

Bibliografisk träff 2012-12-11

A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound, administered as a 24-h continuous infusion in patients with advanced solid tumors.

Gordon MS, Ilaria R, de Alwis DP, Mendelson DS, McKane S, Wagner MM, Look KY, LoRusso PM.

Cancer Chemother Pharmacol · comparative study; research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1007/s00280-012-1917-8

Bibliografisk träff 2012-06-01

Tasisulam sodium (LY573636 sodium) as third-line treatment in patients with unresectable, metastatic non-small-cell lung cancer: a phase-II study.

Scagliotti GV, Ilaria R, Novello S, von Pawel J, Fischer JR, Ermisch S, de Alwis DP, Andrews J, Reck M, Crino L, Eschbach C, Manegold C.

J Thorac Oncol · clinical trial, phase ii; comparative study; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1097/jto.0b013e3182519d79

Bibliografisk träff 2012-04-27

A phase II study of tasisulam sodium (LY573636 sodium) as second-line or third-line treatment for patients with unresectable or metastatic soft tissue sarcoma.

Ryan CW, Matias C, Agulnik M, Lopez-Pousa A, Williams C, de Alwis DP, Kaiser C, Miller MA, Ermisch S, Ilaria R, Keohan ML.

Invest New Drugs · clinical trial, phase ii; multicenter study; journal article · DOI 10.1007/s10637-012-9819-5

Bibliografisk träff 2011-09-08

Tasisulam sodium, an antitumor agent that inhibits mitotic progression and induces vascular normalization.

Meier T, Uhlik M, Chintharlapalli S, Dowless M, Van Horn R, Stewart J, Blosser W, Cook J, Young D, Ye X, Evans G, Credille K, Ballard D, Huber L, Capen A, Chedid M, Ilaria R, Smith MC, Stancato L.

Mol Cancer Ther · journal article · DOI 10.1158/1535-7163.mct-11-0323

Bibliografisk träff 2011-03-31

A phase 2 study of tasisulam sodium (LY573636 sodium) as second-line treatment for patients with unresectable or metastatic melanoma.

Kirkwood JM, Gonzalez R, Reintgen D, Clingan PR, McWilliams RR, de Alwis DP, Zimmermann A, Brown MP, Ilaria RL, Millward MJ.

Cancer · clinical trial, phase ii; research support, non-u.s. gov't; journal article · DOI 10.1002/cncr.26068

Bibliografisk träff 2011-03-23

A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound in patients with refractory solid tumors.

Simon GR, Ilaria RL, Sovak MA, Williams CC, Haura EB, Cleverly AL, Sykes AK, Wagner MM, de Alwis DP, Slapak CA, Miller MA, Spriggs DR.

Cancer Chemother Pharmacol · research support, non-u.s. gov't; research-article; clinical trial, phase i; journal article · DOI 10.1007/s00280-011-1593-0

Bibliografisk träff 2008-11-01

Novel acyl sulfonamide LY573636-sodium: effect on hematopoietic malignant cells.

Haritunians T, Gueller S, O'Kelly J, Ilaria R, Koeffler HP.

Oncol Rep · research support, non-u.s. gov't; research-article; journal article · DOI 10.3892/or_00000135